The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
The opinions or assertions contained herein are the private views of the author and are not to be construed as official or reflecting the views of the US Department of the Army or the Department of Defense.
KantarjianH., GandhiV., KozuchP.Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol.2003; 21(6): 1167–1173.
7.
KantarjianH., GandhiV., CortesJ.Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood.2003; 102(7): 2379–2386.
8.
GandhiV., KantarjianH., FaderlS.Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res.2003; 9(17): 6335–6342.
9.
CooperT., KantarjianH., PlunkettW., GandhiV.Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides, Nucleotides and Nucleic acids.2004; 23(8-9): 1417–1423.
10.
FaderlS., GandhiV., O'BrienS.Results of phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood.2005; 105(3): 940–947.
O'ShaughnessyJ., TjulandinS., DavidsonN.ABI-007 (Abraxane), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: a phase III trial. Proc 26th Ann San Antonio Breast Cancer Symposium.2003; Abstract #44. Available at: www.sabcs.org. Accessed on August 2, 2005.
13.
LeeD.Current trials of a nanoparticle albumin-bound taxane formulation in metastatic breast cancer. Clin Breast Cancer.2004; 4(6): 391–393.
14.
IbrahimN., SamuelsB., PageR.Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in two multicenter phase II studies. Proc Am Soc Clin Oncol.2002; Abstract #209. Available at: www.asco.org. Accessed on March 22, 2005.
15.
IbrahimN., EllerhostJ., TheriaultR.Phase I study of cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel (Abi-007) in solid tumors. Proc Am Soc Clin Oncol.2000; Abstract #609F. Available at: www.asco.org. Accessed on March 22, 2005.
16.
DamascelliB., CantuG., MattavelliF.Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007). Cancer.2001; 92(10): 2592–2602.
17.
DamascelliB., Soon-ShiongP., DesaiN.A novel intra-arterial chemotherapeutic approach to squamous cell cancer of the head and neck and anal cancer using high dose cremaphore-free paclitaxel/albumin nanoparticles (ABI-007). Proc Am Soc Clin Oncol.2000; Abstract #816. Available at: www.asco.org. Accessed on March 22, 2005.
18.
DamascelliB., PatelliG., LanocitaR.Intra-arterial paclitaxel in albumin nanoparticles controls squamous carcinoma at various sites. Proc Am Soc Clin Oncol.2003; Abstract 2050. Available at: www.asco.org. Accessed on March 22, 2005.
19.
BlumJ.L., SavinM., EdelmanG.Long-term disease control in taxane-refractory metastatic breast cancer treated with nab-paclitaxel [poster]. Proc Am Soc Clin Oncol.2004; Abstract #543. Available at: http://asco.org/ac/1,1003,_12-002640-00_18-0026-00_19-003975,00.asp. Accessed on August 22, 2005.
20.
BlumJ.L., BeveridgeR., RobertN.ABI-007 nanoparticle paclitaxel: demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer. Proc Am Soc Clin Oncol.2003; Abstract 64. Available at: www.asco.org. Accessed on March 22, 2005.
21.
O'ShaughnessyJ., BlumJ.L., SandbachJ., SavinM., FenskeE., HawkinsM.Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patient with taxane-refractory metastatic breast cancer [poster]. Breast Cancer Res Treat.2004; 88(suppl 1): S65.
22.
CampbellK., HershE., StopeckA.A phase I trial of ABI-007 administered weekly for three doses every 4 weeks in patients with advanced non-hematologic malignancies. Proc Am Soc Clin Oncol.2002; Abstract #403. Available at: www.asco.org. Accessed on March 22, 2005.
23.
NymanD., CampbellK., HershE.A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies [poster]. J Clin Oncol.2004; 2027.
24.
IbrahimN., DesaiN., LeghaS.Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res.2002; 8(5): 1038–1044.
25.
DesaiN., YaoZ., TrieuV., Soon-Shiong Om DykesD., NokerP.Evidence of greater tumor and red cell partitioning and superior antitumor activity of cremophor free nanoparticle paclitaxel (ABI-007) compared to taxol. Proc Am Soc Clin Oncol.2003; Abstract #625. Available at: www.asco.org. Accessed on March 22, 2005.
26.
SparreboomA., ScriptureC., TrieuV.Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Caner Res.2005; 11(11): 4136–4143.
